Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients.
about
SXR, a novel steroid and xenobiotic-sensing nuclear receptorHuman liver mitochondrial cytochrome P450 2D6--individual variations and implications in drug metabolismRoles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor.Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteersEnvironmental xenobiotics and the antihormones cyproterone acetate and spironolactone use the nuclear hormone pregnenolone X receptor to activate the CYP3A23 hormone response elementPhysiological role of the N-terminal processed P4501A1 targeted to mitochondria in erythromycin metabolism and reversal of erythromycin-mediated inhibition of mitochondrial protein synthesisEvolutionarily divergent electron donor proteins interact with P450MT2 through the same helical domain but different contact pointsFunctional elements associated with hepatic regeneration in living donors after right hepatic lobectomy.Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response.Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up.Summary of information on human CYP enzymes: human P450 metabolism data.The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis.Assessment of drug-drug interactions: concepts and approaches.Measurement of hepatic functional mass by means of 13C-methacetin and 13C-phenylalanine breath tests in chronic liver disease: comparison with Child-Pugh score and serum bile acid levelsReceptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man.Rifampicin and isoniazid increase acetaminophen and isoniazid cytotoxicity in human HepG2 hepatoma cells.Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.Prediction of gestational age-dependent induction of in vivo hepatic CYP3A activity based on HepaRG cells and human hepatocytes.Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytesGut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme inductionSex and age differences in the pharmacokinetics of alosetron.Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?Phenotyping CYP3A using midazolam in cancer and noncancer Asian patientsPopulation pharmacokinetics of weekly docetaxel in patients with advanced cancer.Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.Effect of ABCC2 (MRP2) transport function on erythromycin metabolismEffects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects.Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.The human hepatic cytochromes P450 involved in drug metabolism.OATP1B1 polymorphism as a determinant of erythromycin disposition.Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase.PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics.Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans.Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics.The drug transporter-metabolism alliance: uncovering and defining the interplay.P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity?
P2860
Q22003995-C626DA53-3759-463E-853B-992C1B3F6B02Q24310355-DBB654CE-B0C4-408B-B2A0-54F4C13BACE7Q25255438-DE47A607-4F4D-4A0B-BA07-E43B6CAA9768Q28367567-78F0486A-D243-4024-AA17-2A4A1D2DBD31Q28369384-9BF86A22-2DAA-435C-9806-0E6B9BF3F79CQ28573340-E02F3560-D1D2-43BF-9254-685544FE7A74Q28582715-9777753B-D4AC-4F13-AFDB-569894F18495Q30414609-7CFCCB0F-8F49-4930-90D9-03C196FF5FC0Q30843051-76D8B4DE-0CBC-4EBB-AB03-8D1702EBD5CAQ31420859-8E2B1C60-99BB-4932-847C-063563AD06B8Q32103802-11CC228B-119E-4BFB-B4B0-9E1BD41BA84FQ34357861-E462FEEE-4666-405C-98B6-35BEFFEA586DQ34378923-78672C09-890B-41D2-955A-06F7F2AD0998Q34382446-55039BF0-D227-4856-89E6-B5FDA8258184Q34604457-C315F993-C2D5-42CB-9F28-817E1F3ED6EBQ34737874-13B9F3FD-C98B-451F-B59C-4DA1C3BBE6E0Q35166632-4DE07B82-B0E8-4834-92AC-FA251BBF8A00Q35600241-FA361003-36BF-4A10-9BEE-688178E075DDQ35608569-A14A5E88-F865-4EA3-84D9-B2E17C6100A3Q35802166-1558BBF4-E588-421F-B709-8F349D9ED14DQ35803732-E8372594-A0E7-4C9C-AF86-460F371360E8Q35804217-D52656EB-ABCA-4D83-9DAF-573C1B5892DDQ35825212-EFF13C66-BD59-40EF-90ED-887C7F0FC8A8Q35825890-0D459CB8-D28F-4DD2-9189-BD499EB197DBQ35827661-CFB77A8F-7A9D-402E-850E-2B4FB8591FAEQ35902300-66CD77B3-EB71-4463-8C28-94A067733FA1Q36036374-AD4C8125-46A3-4767-8C19-5B791FF5C00EQ36053651-25940EB2-3C81-486D-A85F-FDE36E6EBE08Q36258518-8E84938E-7B16-4C18-962E-39907C0826BDQ36339094-1CD53652-E0FD-4852-9C09-56204864EE17Q36724323-A30FEE9F-D347-4344-BD07-680DFA44A6F3Q36995453-42AC0352-C11E-4ECE-A771-4F89AB9C5A86Q37074093-3C8CC3D7-1FA3-4B94-92CC-AD376C496553Q37176032-C31AC15B-AB20-48ED-A1B5-4CF976A8EDEBQ37367800-ED861808-742F-4C79-B3E6-8FFDB09753EFQ37405437-32A1C0DB-59CB-48B3-89DC-CC93FAD38F93Q37439697-F1DD8D79-A7A1-43D6-90FF-541EFC0D393CQ37485904-88D47844-28E3-4CBE-95B7-3DE590BC5B1BQ37626608-DDDFC9EB-35C1-4D5D-8F7A-FD629DF08211Q37733572-C953AFB6-9EC2-41E9-B7B5-C033A32854C3
P2860
Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients.
description
1989 nî lūn-bûn
@nan
1989 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Erythromycin breath test as an ...... Studies in rats and patients.
@ast
Erythromycin breath test as an ...... Studies in rats and patients.
@en
Erythromycin breath test as an ...... Studies in rats and patients.
@nl
type
label
Erythromycin breath test as an ...... Studies in rats and patients.
@ast
Erythromycin breath test as an ...... Studies in rats and patients.
@en
Erythromycin breath test as an ...... Studies in rats and patients.
@nl
prefLabel
Erythromycin breath test as an ...... Studies in rats and patients.
@ast
Erythromycin breath test as an ...... Studies in rats and patients.
@en
Erythromycin breath test as an ...... Studies in rats and patients.
@nl
P2093
P2860
P356
P1476
Erythromycin breath test as an ...... Studies in rats and patients.
@en
P2093
D M Heuman
L G Winkelman
P B Watkins
P S Guzelian
S A Murray
S A Wrighton
P2860
P304
P356
10.1172/JCI113933
P407
P577
1989-02-01T00:00:00Z